Simulations Plus (NASDAQ:SLP) Issues FY24 Earnings Guidance

Simulations Plus (NASDAQ:SLP) updated its FY24 earnings guidance on Tuesday. The company provided EPS guidance of $0.54-0.56 for the period, compared to the consensus EPS estimate of $0.55. The company issued revenue guidance of $69-72 million, compared to the consensus revenue estimate of $70.87 million. Simulations Plus also updated its FY 2024 guidance to 0.540-0.560 EPS.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on SLP. Craig Hallum boosted their price objective on Simulations Plus from $51.00 to $56.00 and gave the company a buy rating in a research report on Thursday, June 13th. Oppenheimer boosted their price objective on Simulations Plus from $55.00 to $65.00 and gave the company an outperform rating in a research report on Thursday, June 13th. Finally, William Blair began coverage on Simulations Plus in a research report on Friday, June 28th. They issued an outperform rating for the company.

Simulations Plus Stock Performance

Shares of SLP opened at $46.86 on Wednesday. Simulations Plus has a one year low of $32.69 and a one year high of $52.69. The stock has a market capitalization of $936.73 million, a price-to-earnings ratio of 88.42 and a beta of 0.72. The stock has a 50 day moving average price of $47.81 and a 200 day moving average price of $44.18.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Wednesday, April 3rd. The technology company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.18 by $0.02. Simulations Plus had a return on equity of 7.95% and a net margin of 16.22%. The firm had revenue of $18.31 million during the quarter, compared to analysts’ expectations of $17.31 million. During the same period in the previous year, the business earned $0.20 earnings per share. The firm’s revenue for the quarter was up 16.2% on a year-over-year basis. On average, analysts predict that Simulations Plus will post 0.55 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Daniel L. Weiner sold 3,250 shares of the business’s stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $48.31, for a total transaction of $157,007.50. Following the completion of the sale, the director now directly owns 8,759 shares in the company, valued at $423,147.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Simulations Plus news, Director Daniel L. Weiner sold 3,250 shares of the business’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $48.31, for a total transaction of $157,007.50. Following the transaction, the director now owns 8,759 shares of the company’s stock, valued at $423,147.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $45.95, for a total value of $919,000.00. Following the transaction, the director now directly owns 3,580,857 shares in the company, valued at approximately $164,540,379.15. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 44,500 shares of company stock worth $2,072,198. 20.90% of the stock is owned by corporate insiders.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.